Dear Erowid Readers: We're a small nonprofit that runs the top drug information website in the world. We have only 4 staff but serve 12 million users, and have costs like any big website: servers, power, office space, programs, and staff. To protect our independence, we don't run ads or take government funds. If everyone reading this gave $3, our fundraising would be done today. If Erowid is useful to you, take a minute to keep it online and ad-free another year!
Donate by Bitcoin

Erowid References Database

LeTourneau JL, Hagg DS, Smith SM. 
“Baclofen and gamma-hydroxybutyrate withdrawal”. 
Neurocrit Care. 2008;8(3):430-3.
INTRODUCTION: Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate GHB withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy. METHODS: A case report from the medical intensive care unit ICU of the university tertiary care hospital.
RESULTS: A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.
CONCLUSIONS: Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.
Submit Comment
[ Cite HTML ] Plants & Drugs Mind & Spirit Freedom & Law Arts & Sciences Search About Erowid and Feedback Library & Bookstore Copyrights Memberships noref